Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVAX-008 in Low HBsAg/Negative Chronic Hepatitis B
NCT07204236Phase 1Active, not recruiting
- Sponsor
- Grand Theravac Life Science (Nanjing) Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TVAX-008 in Chronic Hepatitis B (CHB), sponsored by Grand Theravac Life Science (Nanjing) Co., Ltd. Primary endpoint: Hepatitis B Surface Antibody levels at 24 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
TVAX-008
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07204236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204236.